Quarterly report [Sections 13 or 15(d)]

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

v3.25.2
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at beginning at Dec. 31, 2023 $ 723 $ 57,884,815 $ (53,218,853) $ 4,666,685
Balance at beginning, Common shares (in shares) at Dec. 31, 2023 723,411      
Share-Based Compensation   894,523   894,523
Share-Based Payments to Vendors $ 5 305,595   305,600
Share-Based Payments to Vendors (in shares) 4,500      
Issuance of shares of common stock in At-the-Market sales agreement, net of cash issuance costs $ 57 4,299,417   4,299,474
Issuance of shares of common stock in At-the-Market sales agreement, net of cash issuance costs (in shares) 56,983      
Warrant Exercise $ 3 210,196   210,199
Warrant Exercise (in shares) 2,961      
Net Income (Loss)     (4,377,889) (4,377,889)
Balance at ending at Mar. 31, 2024 $ 788 63,594,546 (57,596,742) 5,998,592
Balance at ending, Common shares (in shares) at Mar. 31, 2024 787,855      
Balance at beginning at Dec. 31, 2023 $ 723 57,884,815 (53,218,853) 4,666,685
Balance at beginning, Common shares (in shares) at Dec. 31, 2023 723,411      
Net Income (Loss)       (8,499,715)
Balance at ending at Jun. 30, 2024 $ 800 65,145,243 (61,718,568) 3,427,475
Balance at ending, Common shares (in shares) at Jun. 30, 2024 799,808      
Balance at beginning at Mar. 31, 2024 $ 788 63,594,546 (57,596,742) 5,998,592
Balance at beginning, Common shares (in shares) at Mar. 31, 2024 787,855      
Share-Based Compensation   1,016,998   1,016,998
Share-Based Payments to Vendors $ 5 213,495   213,500
Share-Based Payments to Vendors (in shares) 5,300      
Issuance of shares of common stock in At-the-Market sales agreement, net of cash issuance costs $ 7 320,204   320,211
Issuance of shares of common stock in At-the-Market sales agreement, net of cash issuance costs (in shares) 6,653      
Net Income (Loss)     (4,121,826) (4,121,826)
Balance at ending at Jun. 30, 2024 $ 800 65,145,243 (61,718,568) 3,427,475
Balance at ending, Common shares (in shares) at Jun. 30, 2024 799,808      
Balance at beginning at Dec. 31, 2024 $ 852 67,936,225 (67,321,956) $ 615,121
Balance at beginning, Common shares (in shares) at Dec. 31, 2024 851,534     851,534
Share-Based Compensation   333,598   $ 333,598
Share based compensation to settle accrued compensation   413,120   413,120
Share-Based Payments to Vendors $ 8 110,072   110,080
Share-Based Payments to Vendors (in shares) 7,938      
Issuance of shares of common stock in January Registered Direct Offering, net of cash issuance costs $ 123 2,099,130   2,099,253
Issuance of shares of common stock in January Registered Direct Offering, net of cash issuance costs (in shares) 123,153      
Issuance of shares of common stock and pre-funded warrants in March Registered Direct Offering, net of cash issuance costs $ 107 889,313   889,420
Issuance of shares of common stock and pre-funded warrants in March Registered Direct Offering, net of cash issuance costs (in shares) 107,500      
Pre-funded Warrant Exercise $ 30 (30)    
Pre-funded Warrant Exercise (in shares) 29,750      
Net Income (Loss)     (2,149,193) (2,149,193)
Balance at ending at Mar. 31, 2025 $ 1,120 71,781,428 (69,471,149) 2,311,399
Balance at ending, Common shares (in shares) at Mar. 31, 2025 1,119,875      
Balance at beginning at Dec. 31, 2024 $ 852 67,936,225 (67,321,956) $ 615,121
Balance at beginning, Common shares (in shares) at Dec. 31, 2024 851,534     851,534
Warrant Exercise (in shares)       252,022
Net Income (Loss)       $ (4,395,472)
Balance at ending at Jun. 30, 2025 $ 1,470 75,282,289 (71,717,428) $ 3,566,331
Balance at ending, Common shares (in shares) at Jun. 30, 2025 1,470,352     1,470,352
Balance at beginning at Mar. 31, 2025 $ 1,120 71,781,428 (69,471,149) $ 2,311,399
Balance at beginning, Common shares (in shares) at Mar. 31, 2025 1,119,875      
Share-Based Compensation   324,216   324,216
Share-Based Payments to Vendors $ 11 86,169   86,180
Share-Based Payments to Vendors (in shares) 11,242      
Issuance of shares of common stock related to equity line of credit purchase agreement, net of cash issuance costs $ 117 610,145   610,262
Issuance of shares of common stock related to equity line of credit purchase agreement, net of cash issuance costs (in shares) 116,963      
Issuance of shares of common stock related to warrant exercise, net of cash issuance costs $ 222 2,480,331   2,480,553
Issuance of shares of common stock related to warrant exercise, net of cash issuance costs (in shares) 222,272      
Net Income (Loss)     (2,246,279) (2,246,279)
Balance at ending at Jun. 30, 2025 $ 1,470 $ 75,282,289 $ (71,717,428) $ 3,566,331
Balance at ending, Common shares (in shares) at Jun. 30, 2025 1,470,352     1,470,352